CRL
Charles River Laboratories International, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum-inputs (vergelijkbare managers):
breedte van houders +7.1% ·
aandelenstroom +9.1% ·
netto nieuwe posities +6.7%
— formule
Brede accumulatie — stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 140 | -1 | 45.53M | $10.31B | +6 | −6 |
| Q1 2026 | 143 | -7 | 45.52M | $7.86B | +6 | −14 |
| Q4 2025 | 150 | +3 | 43.69M | $8.72B | +4 | — |
| Q3 2025 | 22 | 0 | 23.18M | $3.62B | +1 | −2 |
| Q2 2025 | 20 | +2 | 21.36M | $3.24B | +4 | −2 |
| Q1 2025 | 15 | 0 | 9.57M | $1.44B | +1 | −1 |
| Q4 2024 | 15 | +1 | 9.65M | $1.78B | +1 | — |
| Q3 2024 | 13 | -1 | 6.67M | $1.31B | — | −1 |
| Q2 2024 | 14 | — | 3.92M | $810.09M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 2 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (passief) | 2.18M | — | $402.66M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passief) | 1.23M | +1.2% | $227.04M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passief) | 1.23M | +1.2% | $227.04M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Norges Bank ✦ (passief) | 535.68K | +1.8% | $98.89M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Millennium Management ✦ | 372.22K | +1952.2% | $68.71M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 13 | PRIMECAP Management ✦ | 272.98K | -0.2% | $50.39M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Fisher Asset Management ✦ | 232.32K | +25.8% | $42.89M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 171.22K | -1.0% | $31.61M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 171.22K | -1.0% | $31.61M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 170.63K | +1101.8% | $31.50M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 170.63K | +1101.8% | $31.50M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 123.69K | +59.9% | $22.83M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 84.66K | Nieuw | $15.63M | 0.0% | New | 1 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 78.86K | +309.6% | $14.56M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 22 | Baillie Gifford ✦ | 75.41K | +9.9% | $13.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 23 | Baillie Gifford ✦ | 75.41K | +9.9% | $13.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 24 | Baillie Gifford ✦ | 75.41K | +9.9% | $13.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 25 | Marshall Wace ✦ | 21.61K | -93.0% | $3.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 26 | Marshall Wace ✦ | 21.61K | -93.0% | $3.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 27 | Marshall Wace ✦ | 21.61K | -93.0% | $3.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 20.98K | -53.0% | $3.87M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 20.98K | -53.0% | $3.87M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 20.98K | -53.0% | $3.87M | 0.0% | ▼ Trim | 3 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| D. E. Shaw & Co. | $15.63M | 0.0% |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 555 houders, 56.84M aandelen, $9.32B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 2.04K aand · $599,711
Director · 573 aand · $163,443
Officer · 3.71K aand · $1.04M
Officer, Director · 6.50K aand · $1.82M
Director · 28.73K aand · $7.90M
Officer · 404 aand · $104,446
Officer · 1.21K aand · $311,529
Officer · 736 aand · $190,278
Officer · 4.18K aand · $1.08M
Officer · 1.27K aand · $330,055
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie